To determine if FGFR inhibition plays a role in Pon efficacy, we next tested the FGFR1 inhibitor sorafenib17, the FGFR1-3 inhibitor pazopanib18, and the pan-FGFR inhibitors dovitinib and lenvatinib19,20 in our VQ MM cell lines. The gene discussed is FGFR1; the disease is Miyoshi myopathy.